RESUMO
COVID-19 has a significant impact on the hematopoietic system and hemostasis. Leukocytosis, lymphopenia, and thrombocytopenia are associated with increased severity and even death in COVID-19 cases. Objective: The aim is to examine the laboratory results of COVID-19 patients from a hospital in the Peruvian Amazon and their clinical prognosis. Material and Methods: An analytical cross-sectional study was carried out whose purpose was to identify the laboratory tests of patients with COVID-19 and mortality in a hospital in Ucayali, Peru during the period from March 13 to May 9, 2020, selecting a total of 127 with Covid-19. Mean and the standard deviation was described for age, leukocytes, neutrophils, platelets, RDW-SD;median and interquartile range for the variables lymphocyte, RN / L, fibrinogen, CRP, D-dimer, DHL, hematocrit, monocytes, eosinophils. Results: No differences were observed in this population regarding death and sex (OR: 1.31;95% CI 0.92 to 1.87), however, it was observed that, for each one-year increase, the probability of death increased by 4% (PR: 1.04, 95% CI 1.03 to 1.05). The IRR (Incidence Risk Ratio) analysis for the numerical variables showed results strongly associated with hematological values such as Leukocytes (scaled by 2500 units) ( IRR: 1.08, 95% CI 1.03 to 1.13), neutrophils (scaled by 2500 units) (IRR: 1.08;95% CI 1.03 to 1.13), on the contrary, it is observed that the increase of 1000 units in lymphocytes, the probability of dying decreased by 48% (IRR: 0.52;95% CI 0.38 to 071). Conclusions: Parameters such as leukocytes,neutrophils and D-dimer were statistically much higher in patients who died.
RESUMO
Introduction: The use of ivermectin in the treatment or prevention against COVID-19 poses a public health problem. Objective: Describe the inappropriate use of ivermectin for the treatment and prevention of COVID-19. Methods: Prospective cross-sectional study. A snowball-type sampler was used. All those who agreed to participate in the study (163) and who agreed to participate voluntarily were interviewed. The participants belonged to the departments of Áncash, Apurímac, Arequipa, Ayacucho, Cajamarca, Callao, Cusco, Huancavelica, Huánuco, Ica, Junín, La Libertad, Lambayeque, Lima, Pasco, Piura, Puno, Tacna and Ucayali (Peru). The study was conducted during the month of May, 2021. Results: 163 participants were surveyed, of which 71 (44%) were men and 92 (56%) women, with a mean age of 56.41 (SD 10.24) and with a minimum of 21 and a maximum of 82 years. The most relevant was the frequent use of ivermectin for the spread of COVID-19, although it was consumed more time by people who used it as prevention method. Conclusions: People consumed ivermectin once or twice a day, without a prescription, as prevention or because they had COVID-19. Those who took it as a preventive method took high doses for a long time putting their health at risk. This situation could be reversed through the proper implementation of science-based directives and a better media information policy.